Johnson & Johnson Showcases Over 20 China Debuts at CIIE 2024, Focusing on Aging Population
Johnson & Johnson
Medical Device R&D and Manufacturer
On November 7, in the exhibition area of the 7th CIIE, Johnson & Johnson launched more than 20 innovative products making their "China debut."Many of them are globally首发 "Made in China" products originating from local innovation.
Zhou Mintao, President of Johnson & Johnson Medical Technology China, stated: "Johnson & Johnson is a 'full attendee' of seven CIIEs. We are accelerating the introduction of numerous innovative exhibits to China and promoting 'Made in China' innovative products, which are produced locally in China, to the global market."
Johnson & Johnson's newly launched products include several varieties targeting the elderly, among which two products that help seniors achieve clear and comfortable vision have drawn attention.
In addition, there are innovative drugs for multiple myeloma, which occurs frequently in the elderly population. One of these drugs was approved to enter the Chinese market in June this year.
In addition to aging-related products, Johnson & Johnson has launched several new products in the fields of cancer and cardiovascular and cerebrovascular diseases this year, the most significant of which is aThe world's first approved EGFR/MET bispecific antibody for the treatment of non-small cell lung cancer.Moreover, Johnson & Johnson revealed that the world's first digital surgical robot for bronchoscopic diagnosis and treatment of lung cancer has entered clinical use in China.
Source: CIIE Venue
Editor: Jiang Yun, Jia Ting
Operation | Han Jinrui
Chinese Innovative Drugs Sold $1 Billion in the U.S. Within Half a Year
2024 CIIE | Pfizer Commits to Invest $1 Billion in China Over the Next Five Years
